Literature DB >> 153333

Complement activation in acne vulgaris: in vitro studies with Propionibacterium acnes and Propionibacterium granulosum.

G F Webster, J J Leyden, M E Norman, U R Nilsson.   

Abstract

To better define the role of bacteria in inflammatory acne vulgaris, we have investigated the ability of four strains of Propionibacterium acnes and three strains of Propionibacterium granulosum to activate complement. Complement activation was assayed by incubating normal human serum with varying concentrations of each strain and measuring residual total hemolytic complement activity. When serum was tested unaltered, P. acnes strains were approximately threefold more potent than an equal weight of P. granulosum in consuming complement, which could reflect classical and/or alternative pathway activation. All strains also consumed complement in serum chelated with ethyleneglycol-bis (beta-aminoethyl ether)-N,N'-tetraacetic acid, which selectively assays alternative pathway activation. Incubation of unaltered serum with both P. acnes and P. granulosum resulted in immunoelectrophoretic conversion of C4, C3, and factor B of the alternative pathway. Incubation of chelated serum resulted in conversion of C3 and factor B. These data taken together suggest that both species can activate complement through either pathway. Serum incubated with P. acnes was chemotactic for polymorphonuclear leukocytes, and this chemotactic activity was largely C5 dependent as shown by antibody inhibition. It is suggested that complement activation may occur in vivo in acne, and the inflammatory response may be contributed to by the generation of C5-dependent chemotactic factors.

Entities:  

Mesh:

Year:  1978        PMID: 153333      PMCID: PMC422187          DOI: 10.1128/iai.22.2.523-529.1978

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  17 in total

1.  Quantification of bacteria in isolated pilosebaceous follicles in normal skin.

Authors:  S M Puhvel; R M Reisner; D A Amirian
Journal:  J Invest Dermatol       Date:  1975-12       Impact factor: 8.551

2.  [A micro-method of immuno-electrophoresis].

Authors:  J J SCHEIDEGGER
Journal:  Int Arch Allergy Appl Immunol       Date:  1955

3.  An in vivo evaluation of the inflammatory effect of purified comedonal components in human skin.

Authors:  S M Puhvel; M Sakamoto
Journal:  J Invest Dermatol       Date:  1977-10       Impact factor: 8.551

4.  A lipid chemotactic factor from anaerobic coryneform bacteria including Corynebacterium parvum with activity for macrophages and monocytes.

Authors:  R J Russell; R J McInroy; P C Wilkinson; R G White
Journal:  Immunology       Date:  1976-06       Impact factor: 7.397

5.  Activation of the alternative complement pathway by pneumococcal cell wall teichoic acid.

Authors:  J A Winkelstein; A Tomasz
Journal:  J Immunol       Date:  1978-01       Impact factor: 5.422

6.  A simple method for producing antibody specific to a single selected diffusible antigen.

Authors:  R B Goudie; C H Horne; P C Wilkinson
Journal:  Lancet       Date:  1966-12-03       Impact factor: 79.321

7.  Reticulostimulating properties of killed vaccines of anaerobic coryneforms and other organisms.

Authors:  C S Cummins; D M Linn
Journal:  J Natl Cancer Inst       Date:  1977-12       Impact factor: 13.506

Review 8.  An overview of acne.

Authors:  A M Kligman
Journal:  J Invest Dermatol       Date:  1974-03       Impact factor: 8.551

9.  Activation of the classical and alternate pathways of complement by Corynebacterium parvum.

Authors:  W H McBride; D M Weir; A B Kay; D Pearce; J R Caldwell
Journal:  Clin Exp Immunol       Date:  1975-01       Impact factor: 4.330

10.  Release of neutrophil chemotactic activity during immediate hypersensitivity reactions in humans.

Authors:  P C Atkins; M Norman; H Weiner; B Zweiman
Journal:  Ann Intern Med       Date:  1977-04       Impact factor: 25.391

View more
  16 in total

Review 1.  Acne: a review of immunologic and microbiologic factors.

Authors:  C G Burkhart; C N Burkhart; P F Lehmann
Journal:  Postgrad Med J       Date:  1999-06       Impact factor: 2.401

Review 2.  [Pathophysiology of acne].

Authors:  C Borelli; G Plewig; K Degitz
Journal:  Hautarzt       Date:  2005-11       Impact factor: 0.751

Review 3.  Dermatology.

Authors:  M H Rustin
Journal:  Postgrad Med J       Date:  1990-11       Impact factor: 2.401

4.  Analysis of the proinflammatory property of epidermal cyst contents: chemotactic C5a anaphylatoxin generation.

Authors:  T Terui; M Rokugo; T Kato; H Tagami
Journal:  Arch Dermatol Res       Date:  1989       Impact factor: 3.017

5.  Inhibitory effect of chlorophyllin on the Propionibacterium acnes-induced chemokine expression.

Authors:  Mi-Sun Kang; Jin-Hee Kim; Boo-Ahn Shin; Hyun-Chul Lee; Youn-Shin Kim; Hae-Soon Lim; Jong-Suk Oh
Journal:  J Microbiol       Date:  2013-12-19       Impact factor: 3.422

6.  Suppression of polymorphonuclear leukocyte chemotactic factor production in Propionibacterium acnes by subminimal inhibitory concentrations of tetracycline, ampicillin, minocycline, and erythromycin.

Authors:  G F Webster; J J Leyden; K J McGinley; W P McArthur
Journal:  Antimicrob Agents Chemother       Date:  1982-05       Impact factor: 5.191

7.  Induction of proinflammatory cytokines by a soluble factor of Propionibacterium acnes: implications for chronic inflammatory acne.

Authors:  B R Vowels; S Yang; J J Leyden
Journal:  Infect Immun       Date:  1995-08       Impact factor: 3.441

8.  Inflammation due to intra-cutaneous implantation of stratum corneum.

Authors:  K Dalziel; P J Dykes; R Marks
Journal:  Br J Exp Pathol       Date:  1984-02

9.  Activation of the alternative pathway of complement in human serum by Propionibacterium acnes (Corynebacterium parvum) cell fractions.

Authors:  G F Webster; U R Nilsson; W P McArthur
Journal:  Inflammation       Date:  1981-06       Impact factor: 4.092

10.  Neutrophil chemotaxis by Propionibacterium acnes lipase and its inhibition.

Authors:  W L Lee; A R Shalita; K Suntharalingam; S M Fikrig
Journal:  Infect Immun       Date:  1982-01       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.